Dutta Partha, Burlingham William J
Department of Surgery; School of Medicine and Public Health; University of Wisconsin; Madison, WI USA.
Chimerism. 2011 Jul;2(3):78-83. doi: 10.4161/chim.2.3.18083. Epub 2011 Jul 1.
Exposure to non-inherited maternal antigens (NIMA) during fetal and neonatal life can result in lifelong maternal microchimerism (MMc) and tolerance to NIMA(+) allografts. We have previously shown that 40-50% of BDF1 female x B6 male offspring have multi-organ and multi-lineage MMc, while 70% have evidence of acquired maternal class I antigen in circulating PBMC and splenocytes. These features correlated with the presence of NIMA(d)-specific CD4(+) Treg cells, while offspring lacking MMc also lacked NIMA-specific Tregs. Furthermore, after a DBA/2 heart transplant, NIMA(d)-specific CD4(+) Treg cells rapidly mobilize to the allograft where they produce IL10 and TGFβ, suppressing early acute rejection, while mice deficient in MMc and NIMA(d)-specific Treg reject, allowing IFNγ-producing T effector cells to predominate in the grafts. We hypothesized that maternal cells occupy key sites of alloantigen presentation after transplant, sustaining pre-existing host Treg amidst a rising tide of donor alloantigen released from the graft. Using quantitative PCR to detect GFP transgeneic maternal cells, we found that transplant tolerance was associated with elevated MMc levels in blood, heart & lung, but surprisingly, not in liver. Rejection was associated with significantly lower levels of MMc in CD11b(+) (p = 0.0001) and CD11c(+) (p = 0.045) splenocytes, but not with differences in T cell MMc. Furthermore, compared with low pre-transplant baseline rate of maternal antigen acquisition, long-term graft survival was associated with an increased mean % of cells in blood [0.5% pre vs. 5.0% post] and spleen that were dimly positive for H-2K(d), indicative of de novo cell-surface alloantigen acquisition from the DBA/2 donor heart allograft. In contrast, NIMA-exposed mice that rejected their DBA/2 graft showed a transient increase in H-2K(d-dim) cells in blood during rejection (day 9-12) but a complete absence of donor MHC acquisition 100 days after transplant. As was the case prior to transplant, antigen acquisition was largely confined to MHC class II+ professional APC.
When a NIMA-expressing organ allograft is accepted, MMc persists, mainly distributed into the antigen-presenting cell compartment, where the bulk of graft-derived alloantigen for "semi-direct" presentation is also present.
在胎儿期和新生儿期接触非遗传的母体抗原(NIMA)可导致终身母体微嵌合体(MMc)以及对NIMA(+)同种异体移植物的耐受。我们之前已表明,40 - 50%的BDF1雌性×B6雄性后代具有多器官和多谱系MMc,而70%的后代在循环外周血单个核细胞(PBMC)和脾细胞中有获得性母体I类抗原的证据。这些特征与NIMA(d)特异性CD4(+)调节性T细胞(Treg)的存在相关,而缺乏MMc的后代也缺乏NIMA特异性Treg。此外,在进行DBA/2心脏移植后,NIMA(d)特异性CD4(+) Treg细胞迅速迁移至同种异体移植物,在那里它们产生白细胞介素10(IL10)和转化生长因子β(TGFβ),抑制早期急性排斥反应,而缺乏MMc和NIMA(d)特异性Treg的小鼠则发生排斥反应,使得产生干扰素γ(IFNγ)的效应T细胞在移植物中占主导地位。我们推测,母体细胞在移植后占据同种异体抗原呈递的关键位点,在从移植物释放的供体同种异体抗原不断增加的情况下维持预先存在的宿主Treg。使用定量聚合酶链反应(PCR)检测绿色荧光蛋白(GFP)转基因母体细胞,我们发现移植耐受与血液、心脏和肺中MMc水平升高相关,但令人惊讶的是,肝脏中并非如此。排斥反应与CD11b(+)(p = 0.0001)和CD11c(+)(p = 0.045)脾细胞中MMc水平显著降低相关,但与T细胞MMc的差异无关。此外,与移植前母体抗原获取的低基线率相比,长期移植物存活与血液中细胞平均百分比增加相关[移植前为0.5%,移植后为5.0%],并且脾脏中H - 2K(d)弱阳性细胞增加,这表明从DBA/2供体心脏同种异体移植物中重新获得细胞表面同种异体抗原。相比之下,排斥其DBA/2移植物的NIMA暴露小鼠在排斥期间(第9 - 12天)血液中H - 2K(d - dim)细胞短暂增加,但移植后100天完全没有获得供体主要组织相容性复合体(MHC)。与移植前情况一样,抗原获取主要局限于MHC II类+专业抗原呈递细胞(APC)。
当表达NIMA的器官同种异体移植物被接受时,MMc持续存在,主要分布到抗原呈递细胞区室,“半直接”呈递的大部分移植物来源的同种异体抗原也存在于此。